EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection

Nikolas Weigl iD, Claire Pleimelding iD, Leonard Gilberg, Duc Huynh, Isabel Brand, Jan Bruger, Jonathan Frese, Tabea M Eser, Mohamed I M Ahmed, Jessica M Guggenbuehl-Noller, Renate Stirner, Michael Hoelscher und 5 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0325923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Nikolas Weigl und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany, Member of the German Center for L…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst, Klinikum der Universität München, Helmholtz Zentrum München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Memory T cells play an important role in mediating long-lasting adaptive immune responses to viral infections, such as SARS-CoV-2. In the context of the latter, much of our current knowledge stems from studies in vaccinated individuals or repeatedly infected individuals. However, limited knowledge is available on these responses in fully naive individuals in German communities. We performed immunophenotyping of a previously naive SARS-CoV-2 cohort in convalescent individuals after asymptomatic to moderate COVID-19. The samples were collected median 250 days post infection during the first wave of the COVID pandemic in Germany (March – May 2020). In this cohort of 174 individuals, we phenotyped different leukocyte cell populations in peripheral blood (B, T and Natural Killer cells). We then assessed the serostatus against the SARS-CoV-2 antigens Nucleocapsid (N) and Spike subunit (S1) with its receptor binding domain (RBD), as these are important correlates of protection, by testing for presence of immunoglobulin G (IgG) antibodies. We also measured IgG antibody responses against the N antigen of the common cold coronaviruses HCoV-OC43, HCoV-HKU1, HCoV-NL63 and HCoV-229E, to determine possible cross-reactivity. In a subset of the cohort (n = 76), we performed intracellular staining assays (ICS) after stimulation with SARS-CoV-2 and HCoV antigens. Key findings are significant differences in frequency of CD4+ memory T cell populations, notably CD4+ T EM and CD4+ T EMRA cells, between the group of SARS-CoV-2 positive individuals and the control group. These differences correlated with cytokine production (TNFα, IFNγ) after stimulation with SARS-CoV-2 peptides, indicating a specific T cell immune response. In conclusion, a clear memory T cell and humoral response can be detected up to 250 days post mild to moderate COVID-19 disease. Our results underline findings reported by others indicating a lasting cellular immune response even in a population which previously had not been exposed to SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2AdultAgedFemaleHumansMaleMiddle AgedAntibodies, ViralGermanyImmunoglobulin GImmunologic MemoryMemory T CellsSpike Glycoprotein, CoronavirusUnvaccinated Persons

Substanzen

Antibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany, Member of the German Center for Lung Research (DZL).
  • Department of Infectious Diseases, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.
  • German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany.

ORCID-Profile: Nikolas Weigl, Claire Pleimelding, Julia Roider

Förderung

  • Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst
  • Klinikum der Universität München
  • Helmholtz Zentrum München
  • Universität Bonn
  • Universität Bielefeld
  • Munich Center of Health
  • Deutsche Forschungsgesellschaft
  • Volkswagen Foundation

Zitieren

APA

Weigl, N., Pleimelding, C., Gilberg, L., Huynh, D., Brand, I., Bruger, J., Frese, J., Eser, T. M., Ahmed, M. I. M., Guggenbuehl-Noller, J. M., Stirner, R., Hoelscher, M., Pritsch, M., Geldmacher, C., Kobold, S., Roider, J., & KoCo19-/ORCHESTRA-study group (2025). Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection. PLOS One. https://doi.org/10.1371/journal.pone.0325923

Vancouver

Weigl N, Pleimelding C, Gilberg L, Huynh D, Brand I, Bruger J, et al. Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection. PLOS One. 2025. doi:10.1371/journal.pone.0325923

BibTeX
@article{Weigl2025,
  author = {Weigl, Nikolas and Pleimelding, Claire and Gilberg, Leonard and Huynh, Duc and Brand, Isabel and Bruger, Jan and Frese, Jonathan and Eser, Tabea M and Ahmed, Mohamed I M and Guggenbuehl-Noller, Jessica M and Stirner, Renate and Hoelscher, Michael and Pritsch, Michael and Geldmacher, Christof and Kobold, Sebastian and Roider, Julia and KoCo19-/ORCHESTRA-study group, KoCo19-/ORCHESTRA-study group},
  title = {Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325923}
}
Kostenlos starten →